The ENVISAGE-TAVI AF Trial and Its Implications for the Anticoagulation of AF Patients after TAVR, Vol. 1
During the Hot Line session of the ESC Congress 2021, the results of the ENVISAGE-TAVI AF trial, which consisted of patients from Japan, were presented. These results, which were also published in The New England Journal of Medicine, showed that edoxaban was non-inferior to vitamin K antagonists (VKAs) in the evaluation of adverse clinical events after TAVR in patients with atrial fibrillation (AF).
TCROSS NEWS spoke with Dr. Yusuke Watanabe of Teikyo University, Dr. Kentaro Hayashida of Keio University, and Dr. Masanori Yamamoto of Toyohashi Heart Center, who all served as investigators of the ENVISAGE-TAVI AF trial, about the results of the study.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
![[ Live video Part.2 ] Treatment Strategies for LAD Ostial CTO Lesions: Keys to Procedural Success](https://tcross-static.s3.ap-northeast-1.amazonaws.com/global/article/6487/og_6487_11.png)
![[ Live video Part.1 ] Optimal Treatment Strategies for Severe Calcified Lesions Using Advanced Debulking Techniques](https://tcross-static.s3.ap-northeast-1.amazonaws.com/global/article/6486/og_6486_11.png)